Literature DB >> 22672123

Drivers for change in the management of prostate cancer - guidelines and new treatment techniques.

J M Wolff1, M Mason.   

Abstract

Clinical practice guidelines and new treatment techniques are of particular importance for the effective management of prostate cancer. In Europe, the European Association of Urology guidelines offer a regularly updated evidence-based source of recommendations for the optimal treatment of prostate cancer. This review examines recent changes to guidelines highlighting developments in diagnosis, hormonal therapy in advanced and metastatic disease, bone protection, the definition of new terminology such as castrate-resistant prostate cancer, treatment of relapse after hormonal therapy, and cytotoxic therapy for castrate-resistant prostate cancer. The review also examines new surgical and radiotherapeutic developments in prostate cancer. This includes minimally invasive techniques such as robot-assisted radical prostatectomy, which is becoming the surgical gold standard for clinically localized disease in many countries. Other promising techniques reviewed include cryosurgical ablation of the prostate, laser-induced interstitial thermotherapy, vascular-targeted photodynamic therapy, and high-intensity focused ultrasound; with the exception of cryotherapy, these approaches are not currently recommended for routine clinical use. Finally, we will review the evidence supporting intensity modulated radiotherapy, an optimized high-precision form of three-dimensional conformal radiotherapy which aims to allow homogeneously increased radiation doses, without increased toxicity to healthy at-risk organs. Novel techniques such as proton beam or carbon ion radiotherapy, which may offer improved and more localized dose distribution with reduced damage to normal tissue, are also examined.
© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22672123     DOI: 10.1111/j.1464-410X.2012.11218.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

1.  Implementation of intensity modulated radiotherapy for prostate cancer in a private radiotherapy service in Mexico.

Authors:  María Adela Poitevin-Chacón; Gabriel Reséndiz González; Adriana Alvarado Zermeño; Jesús Manuel Flores Castro; Christian Haydée Flores Balcázar; Samuel Rosales Pérez; Miguel Angel Pérez Pastenes; Alejandro Rodríguez Laguna; Patricio Vázquez Fernández; Alejandro Calvo Fernández; Jorge Bastida Ventura
Journal:  Rep Pract Oncol Radiother       Date:  2014-12-12

2.  Quantitative assessment of cancer vascular architecture by skeletonization of high-resolution 3-D contrast-enhanced ultrasound images: role of liposomes and microbubbles.

Authors:  F Molinari; K M Meiburger; P Giustetto; S Rizzitelli; C Boffa; M Castano; E Terreno
Journal:  Technol Cancer Res Treat       Date:  2013-11-04

3.  The role of cryosurgery of the prostate for nonsurgical candidates.

Authors:  Shadi Al Ekish; Mohammed Nayeemuddin; Michael Maddox; Gyan Pareek
Journal:  JSLS       Date:  2013 Jul-Sep       Impact factor: 2.172

4.  Enzalutamide in European and North American men participating in the AFFIRM trial.

Authors:  Axel S Merseburger; Howard I Scher; Joaquim Bellmunt; Kurt Miller; Peter F A Mulders; Arnulf Stenzl; Cora N Sternberg; Karim Fizazi; Mohammad Hirmand; Billy Franks; Gabriel P Haas; Johann de Bono; Ronald de Wit
Journal:  BJU Int       Date:  2014-10-23       Impact factor: 5.588

Review 5.  Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer.

Authors:  Alan Dal Pra; Jennifer A Locke; Gerben Borst; Stephane Supiot; Robert G Bristow
Journal:  Front Oncol       Date:  2016-02-16       Impact factor: 6.244

6.  Expression of miR-30c and miR-29b in prostate cancer and its diagnostic significance.

Authors:  Chuanan Zhu; Xiumei Hou; Jiabin Zhu; Chunxiao Jiang; Wei Wei
Journal:  Oncol Lett       Date:  2018-06-21       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.